Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

To the Editor.

To the Editor. Abstract —I was most interested in your report of cimetidine-induced potentiation of carmustine and cranial irradiation. We have recently investigated the interaction of cimetidine augmentation of cyclophosphamide in mice. The results1 showed substantial increases (near doubling) in the antitumor activity of cyclophosphamide in mice given concomitant cimetidine therapy. We have previously seen cimetidine augmentation of theophylline levels in man and, taken together, the mechanism in both situations is most probably cimetidine blockade of cytochrome P450 metabolism. Since carmustine is extensively metabolized by P450 mixed-function oxidase systems, your findings of a notable interaction are consonant with this explanation. Your timely report on this interaction should have immediate relevance to the practicing oncologist. References 1. Dorr RT, Alberts DS: Interaction of CMT-augmentation of cyclophosphamide in mice. Br J Cancer 1982;45:35-43.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

To the Editor.

Abstract

Abstract —I was most interested in your report of cimetidine-induced potentiation of carmustine and cranial irradiation. We have recently investigated the interaction of cimetidine augmentation of cyclophosphamide in mice. The results1 showed substantial increases (near doubling) in the antitumor activity of cyclophosphamide in mice given concomitant cimetidine therapy. We have previously seen cimetidine augmentation of theophylline levels in man and, taken together, the mechanism in...
Loading next page...
 
/lp/american-medical-association/to-the-editor-Hr0l0VS0PB
Publisher
American Medical Association
Copyright
Copyright © 1982 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1982.00340230221041
Publisher site
See Article on Publisher Site

Abstract

Abstract —I was most interested in your report of cimetidine-induced potentiation of carmustine and cranial irradiation. We have recently investigated the interaction of cimetidine augmentation of cyclophosphamide in mice. The results1 showed substantial increases (near doubling) in the antitumor activity of cyclophosphamide in mice given concomitant cimetidine therapy. We have previously seen cimetidine augmentation of theophylline levels in man and, taken together, the mechanism in both situations is most probably cimetidine blockade of cytochrome P450 metabolism. Since carmustine is extensively metabolized by P450 mixed-function oxidase systems, your findings of a notable interaction are consonant with this explanation. Your timely report on this interaction should have immediate relevance to the practicing oncologist. References 1. Dorr RT, Alberts DS: Interaction of CMT-augmentation of cyclophosphamide in mice. Br J Cancer 1982;45:35-43.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Oct 1, 1982

References